Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

This study is a prospective, single-arm, phase 2 clinical trial assessing the feasibility, efficacy, and safety of the PD-L1 inhibitor Benmelstobart (TQB2450) as an adjuvant therapy regimen in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma without EGFR active mutations or ALK rearrangement.

Trial Details

NCT ID
NCT06528847
Phase
PHASE2
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Benmelstobart
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Participants are able to understand the informed consent form, voluntarily agree to participate, and sign the informed consent form;
  • Participants must be 18 years or older and under 75 years of age on the day they sign the informed consent form;
  • Pathologically confirmed stage IB (AJCC TNM staging, 8th edition) lung adenocarcinoma;
  • Achieved complete resection (R0) after lobectomy, bilobectomy, or sleeve resection;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →